While annual HIV surveillance reports released by the CDC in May showed that the number of estimated new HIV infections per ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

The measure waives the need for a primary care physician’s prescription for HIV medications like PrEP and Doxy PEP.

Oct. 15 is National Latinx AIDS Awareness Day, focusing on the impact of HIV in Hispanic/Latinx communities while promoting effective ways to prevent, treat and stop the transmission of HIV.

Following the passing of popular Benga songstress Princess Jully this past weekend, fans and Kenyans have come out to honour ...

In order to counter such stigma and discrimination, women living with HIV and Hepatitis B came together at The Voice of ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...

Babies born to mothers with HIV should receive HIV drugs within six hours after birth to prevent mother-to-child transmission ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...